Articles

Look at what’s new in D.C.

Program for 2011 BIO International Convention seeks to provide attendees with a well-rounded knowledge base they can use to advance business objectives
Written byJeffrey Bouley
| 13 min read

Program for 2011 BIO International Convention seeks to provide attendees with a well-rounded knowledge base they can use to advance business objectives

WASHINGTON, D.C.—With themes for its 2011 BIO International Convention focused around the concepts of "Leadership, Partnerships and Breakthroughs," the Biotechnology Industry Organization (BIO) brings insights into the business of biotech to Washington, D.C., this year—the city where BIO itself is headquartered—after a jaunt to Chicago last year for the event.

BIO bills the event as a place where decision-makers in various biotechnology industries come to form partnerships, evaluate the latest technologies and discover new players, adding that "the BIO Exhibition is where they get a snapshot of the evolving industry each year."

The exhibition, like the rest of the June 27-30 convention, is being held at the Walter E. Washington Convention Center, and the exhibits will be broken down into five themed, or "product focus," areas. There is the BioProcess Zone, where you can see companies and organizations focused on upstream and downstream processing, manufacturing, custom outsourcing, information technology and regulatory compliance; the Clinical Trials Zone, focused on clinical trial management, injectable delivery technologies, oral drug delivery technologies, biomarkers and the U.S. Food and Drug Administration's (FDA) Critical Path; the Contract Services Zone, with its biopharmaceutical and pharmaceutical contract research and manufacturing entities ranging from preclinical to clinical to commercial; the Discovery Zone, a place to find new and unique techniques for developing innovations in imaging, lab automation and supplies, software and hardware; and the Business Services Zone, where such players as law firms, logistics providers, consulting firms, office equipment/services and business support organizations can be found.

The exhibit floor pretty much covers the "breakthrough" part of its three-part theme, but what about "leadership" and "partnerships?"

For the former, BIO is highlighting its "Can't-Miss Monday" programming, which it says will feature "some of the biggest names in biotech." Those Monday programs begin with "Biotech Primer: Bio-Baffled?" at 10 a.m., and continues with "Leadership Summit: Deploying Agricultural and Industrial Biotechnologies to Meet Development Challenges" from 1 p.m. to 4:15 p.m. and "Translational Research Forum and Reception: Translational Medicine—A Global Endeavor" from 1 p.m. to 6 p.m.

That isn't the only leadership-themed set of offerings, of course, and another one of note is the new "Emerging Leaders Workshop: Invest in Your Company's Future." The workshop is designed for mid-level product planners and marketing managers who have two to five years of experience and would like to master the skills of strategic planning, collaboration and logistics to successfully bring new products to the market. It will take place Monday, June 27 from 8:45 a.m. to 5 p.m. and Tuesday, June 28, from 8:45 a.m. to 12:30 p.m.

Finally, the "partnering" part can be found in its most obvious form at the BIO Business Forum, which takes place more or less from 8 a.m. to 4:30 Tuesday, Wednesday and

Thursday—although the Tuesday part of the "partnering" begins at 10 a.m. and is both preceded and overlapped by Business Forum company presentations from 9 a.m. to 11 a.m.

BIO encourages attendees to come to the partnering events with a team and be ready to discuss strategic goals.

"Thousands of companies from around the world and across all industry segments will be in the BIO Business Forum with a shared goal—to build relationships that lead to successful partnerships and breakthrough solutions," touts Jim Greenwood, BIO's president and CEO. Through its BIO One-on-One Partnering system, BIO expects to facilitate more than 17,000 face-to-face meetings involving more than 2,100 companies, all in three days.

Super-session me!

Six 'super sessions' provide high-level perspectives on hot topics

The Super Sessions at the 2011 BIO International Convention will give C-level executives and other notable representatives from major companies a chance to "lead broad c

onversations on the state of the global industry, emerging trends and recommended courses of action for biotech companies," according to Jim Greenwood, BIO's president and CEO.

Three of the six sessions are on Tuesday, with the first being Ernst & Young's "25th Annual Biotechnology Industry Report" from 10 a.m. to 11:30 a.m., which will discuss implications for biotech companies as they face a more uncertain future in the current business climate. The session will explore new approaches to deal with current economic realities; creative partnering strategies to deal with a capital-constrained, risk-averse, high-scrutiny environment; ways to engage regulators and payers; and more.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of a single cell surrounded by small molecular particles in a red biological environment.
Measuring mRNA and protein together at single cell resolution can uncover tumor-specific signaling activity and immune features.
Illustration of an antibody intertwined with a DNA double helix.
Discover how CRISPR and single-cell RNA sequencing can connect disease-associated variants to regulatory elements, genes, and pathways.
Digital illustration of the human digestive system highlighting the liver, stomach, and intestines.
Explore how human gut-liver models can improve the translation of preclinical findings into clinical pharmacokinetic predictions.